bristol myers squibb sotyktu

Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success

Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to 'Strong Buy'.

PMLiVE · 5d

Bristol Myers Squibb shares five-year results for Sotyktu in plaque psoriasis

Bristol Myers Squibb (BMS) has shared positive five-year results from a long-term extension (LTE) study of its oral TYK2 inhibitor Sotyktu (deucravacitinib) in adults with moderate-to-severe plaque psoriasis.

Law · 3d

Bristol Myers Squibb GC to Retire After 33 years With Drugmaker

Sandra Leung began her legal career prosecuting homicides, a formative experience that she once said taught her "to make decisions quickly and to be accountable for those decisions."

Business Insider · 2d

Bristol-Myers Squibb (BMY) Gets a Hold from Bernstein

Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) yesterday and set a price target of

MarketWatch · 2d

Bristol Myers Squibb Co. stock outperforms competitors on strong trading day

Shares of Bristol Myers Squibb Co. BMY rose 1.47% to $55.79 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.43% to 6,117.

GlobalData on MSN6d

Bristol Myers Squibb’s Sotyktu shows consistent safety profile in psoriasis trial

US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...

Bristol Myers reports no new safety signals observed in five-year Sotyktu data

Squibb announced new five-year results from the POETYK PSO long-term extension trial of Sotyktu treatment in adult patients ...

Pharmabiz5d

Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis

Bristol Myers Squibb announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque ...

New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis

No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu ...

Bristol Myers announces new five-year results from POETYK PSO trial

Squibb announced new five-year results from the POETYK PSO long-term extension, LTE, trial of Sotyktu treatment in adult ...

Bristol Myers Squibb Names New GC as Legal Chief Retires

Bristol Myers Squibb Co. said Cari Gallman, the company’s executive vice president for corporate affairs, will become its ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results